<DOC>
	<DOCNO>NCT00345956</DOCNO>
	<brief_summary>To provide specific data immunogenicity GSK Biologicals ' HRV liquid vaccine , co-administered routine Expanded Program Immunization ( EPI ) Vietnam . The study also assess reactogenicity safety HRV liquid vaccine relative placebo</brief_summary>
	<brief_title>To Evaluate Immunogenicity , Reactogenicity &amp; Safety 2 Doses GSK Bio HRV Liquid Vaccine Given Infants ( Vietnam )</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female infant , include , 6 10 week age birth weight &gt; 2000 gram . Written inform consent obtain parent guardian subject . Use investigational nonregistered product ( drug vaccine ) HRV liquid vaccine placebo within 30 day precede first dose HRV liquid vaccine placebo , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol except DTPw , HBV OPV vaccine within 14 day dose HRV liquid vaccine placebo end 14 day . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . History allergic disease reaction likely exacerbate component HRV liquid vaccine placebo .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prophylaxis gastroenteritis cause Rotavirus</keyword>
</DOC>